ACTA2 and Glomerular sclerosis: Furthermore, SFN treatment (5/6NX + HA + SFN group) significantly reduced the fibrosis area, glomerular sclerosis index, and fibrotic protein levels (COL1A1, VIM, and ACTA2) compared with those in the 5/6NX + HA group (Figure 7B).